MDR1、CYP2D6和CYP2C19基因多态性与偏头痛预防性治疗反应的关联。
Association of MDR1, CYP2D6, and CYP2C19 gene polymorphisms with prophylactic migraine treatment response.
作者信息
Atasayar Gulfer, Eryilmaz Isil Ezgi, Karli Necdet, Egeli Unal, Zarifoglu Mehmet, Cecener Gulsah, Taskapilioglu Ozlem, Tunca Berrin, Yildirim Oznur, Ak Secil, Tezcan Gulcin, Can Fatma Ezgi
机构信息
Uludag University, Faculty of Medicine, Department of Neurology, Turkey.
Uludag University, Faculty of Medicine, Department of Medical Biology, Turkey.
出版信息
J Neurol Sci. 2016 Jul 15;366:149-154. doi: 10.1016/j.jns.2016.05.019. Epub 2016 May 13.
Prophylactic therapy response varies in migraine patients. The present study investigated the relationship between the resistance to the drugs commonly used in prophylactic therapy and the possible polymorphic variants of proteins involved in the metabolism of these drugs. Migraine patients with the MDR1 3435TT genotype exhibited a better treatment response to topiramate than migraine patients with the CC and CT genotypes (p=0.020). The MDR1 C3435T polymorphism was also found to be a higher risk factor for topiramate treatment failure in a comparison of the number of days with migraine (β2=1.152, p=0.015). However, there was no significant relationship between the treatment response to topiramate and either the CYP2D6 or CYP2C19 polymorphism, and there were no significant correlations between the treatment responses to amitriptyline, propranolol, and valproic acid and the MDR1, CYP2D6 and CYP2C19 gene polymorphisms. This is the first study to investigate the effect of the polymorphic variants on prophylactic therapy response in migraine patients.
预防性治疗在偏头痛患者中的反应各不相同。本研究调查了预防性治疗中常用药物的耐药性与这些药物代谢相关蛋白质的可能多态性变体之间的关系。与携带CC和CT基因型的偏头痛患者相比，携带MDR1 3435TT基因型的偏头痛患者对托吡酯的治疗反应更好（p = 0.020）。在比较偏头痛发作天数时，还发现MDR1 C3435T多态性是托吡酯治疗失败的更高风险因素（β2 = 1.152，p = 0.015）。然而，托吡酯的治疗反应与CYP2D6或CYP2C19多态性之间没有显著关系，阿米替林、普萘洛尔和丙戊酸的治疗反应与MDR1、CYP2D6和CYP2C19基因多态性之间也没有显著相关性。这是第一项研究多态性变体对偏头痛患者预防性治疗反应影响的研究。
Zotero 插件